Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
September 19, 2024 08:00 ET
|
Evaxion Biotech
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction featureThe launch will expectedly...
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
September 16, 2024 07:00 ET
|
Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
September 09, 2024 08:00 ET
|
Evaxion Biotech
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16...
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
September 09, 2024 07:00 ET
|
Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
August 14, 2024 07:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
August 12, 2024 07:27 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
August 08, 2024 08:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is...
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
July 16, 2024 07:30 ET
|
Evaxion Biotech
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art...
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
July 03, 2024 08:05 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
June 26, 2024 07:30 ET
|
Evaxion Biotech
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the inventionUnique Attributes and...